H.C. Wainwright lowered the firm’s price target on United Therapeutics (UTHR) to $400 from $425 and keeps a Buy rating on the shares. The firm estimates a decrease in Tyvaso’s penetration due to increased competition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Cautious Hold Rating on United Therapeutics Amid TETON Study Skepticism and Competitive Risks
- United Therapeutics Reports Record Q2 2025 Financial Results
- United Therapeutics: Strong Growth Potential and Strategic Moves Justify Buy Rating
- United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis
- United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment